



November 15, 2025

The Manager (CRD) The BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai- 400001	The Manager – Listing Department National Stock Exchange of India Ltd Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (East) Mumbai - 400 051
Scrip Code: 530117	Symbol: PRIVISCL

Dear Sir / Madam,

Sub: Outcome of the Board Meeting held on November 15, 2025, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject and in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), please note that the Board of Directors of the Company (“**Board**”), at its meeting held on Saturday, November 15, 2025, which commenced at 11:00 a.m. and concluded at 11.45 a.m., has considered and approved the withdrawal of the Scheme of Amalgamation of Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited with the Company and their respective shareholders.

Accordingly, the information pursuant to Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 is enclosed as Annexure I.

We request you to take the above information on record.

Thanking you,

Yours faithfully,

For **Privi Speciality Chemicals Limited**

Ashwini Saumil Shah
Company Secretary

Encl: As above



PRIVI SPECIALITY CHEMICALS LIMITED

Knowledge Centre & Regd. Office : Privi House, A-71, TTC, Thane Belapur Road, Near Kopar Khairane Railway Station, Navi Mumbai - 400 710, India | Tel. : +91 22 68713200 / 33043500 / 33043600 / 27783040 / 27783041 / 27783045
Fax: +91 22 27783049 / 68713232 | Email: enquiry@privi.co.in | Web: www.privic.com | CIN: L15140MH1985PLC286828



ANNEXURE I

Details as required under SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

Sr. No.	Particulars	Details
1	Name of regulatory or licensing authority	BSE Limited and National Stock Exchange of India Limited
2	Brief details of approval/license - obtained/withdrawn/surrendered	Withdrawal of Scheme of Amalgamation of Privi Fine Sciences Private Limited and Privi Biotechnologies Private Limited with Privi Speciality Chemicals Limited and their respective shareholders under Section 230 to 232 of the Companies Act, 2013
3	Impact/ relevance of such approval/license to the listed entity	The impact pertains primarily to a delay in filings. The Company proposes to refile the application shortly.
4	Withdrawal/ Cancellation or suspension of license/approval by the regulatory or licensing authority, with reasons for such action, estimated impact on (monetary or otherwise) listed entity and penalty, if any	Withdrawal of Scheme of Amalgamation was a voluntary decision of the Board based on the observations received from the Stock Exchanges.
5	Period for which such approval/license is/was valid	Not Applicable
6	Subsequently, the listed entity shall inform the stock exchange (s) the actual impact	The Company hereby has announced the withdrawal of application submitted to Stock Exchanges and since the Company proposes to refile the Scheme shortly, it confirms that no adverse impact is expected to arise from the withdrawal of the Scheme of Amalgamation.



PRIVI SPECIALITY CHEMICALS LIMITED

Knowledge Centre & Regd. Office : Privi House, A-71, TTC, Thane Belapur Road, Near Kopar Khairane Railway Station, Navi Mumbai - 400 710, India | Tel. : +91 22 68713200 / 33043500 / 33043600 / 27783040 / 27783041 / 27783045
Fax: +91 22 27783049 / 68713232 | Email: enquiry@privi.co.in | Web: www.privico.com | CIN: L15140MH1985PLC286828